69
Views
10
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution

, , , , , , , , & show all
Pages 1968-1975 | Received 24 May 2007, Accepted 13 Jul 2007, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Lisa Giulino-Roth, Tara O’Donohue, Zhengming Chen, Tanya M. Trippett, Elizabeth Klein, Nancy A. Kernan, Rachel Kobos, Susan E. Prockop, Andromachi Scaradavou, Neerav Shukla, Peter G. Steinherz, Alison J. Moskowitz, Craig H. Moskowitz & Farid Boulad. (2018) Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leukemia & Lymphoma 59:8, pages 1861-1870.
Read now
J. A. Shafer, H. E. Heslop, M. K. Brenner, G. Carrum, M. F. Wu, H. Liu, N. Ahmed, S. Gottschalk, R. Kamble, K. S. Leung, G. D. Myers, C. M. Bollard & R. A. Krance. (2010) Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leukemia & Lymphoma 51:4, pages 664-670.
Read now
Elena Cavalieri, Angela Matturro, Giorgia Annechini, Federico De Angelis, Natalia Frattarelli, Fabiana Gentilini, Lavinia Grapulin, Mikael Sacco, Fabio Torelli, Marco Vignetti, Franco Mandelli, Robin Foà & Alessandro Pulsoni. (2009) Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkinlymphoma. Leukemia & Lymphoma 50:11, pages 1803-1808.
Read now

Articles from other publishers (7)

Ezel ELGUN, Vildan GÜRSOY, Tuba ERSAL, İbrahim Ethem PINAR, Fahir ÖZKALEMKAŞ & Vildan OZKOCAMAN. (2022) Relaps/Refrakter Hodgkin Lenfoma Hastalarının Otolog Hematopoetik Kök Hücre Nakil Sonuçları ve Risk Faktörü Etkilerinin Retrospektif DeğerlendirilmesiRetrospective Evaluation of the Results of Autologous Hematopoietic Stem Cell Transplantation and the Effects of Risk Factors in Patients With Relaps/Refractory Hodgkin Lymphoma. Uludağ Üniversitesi Tıp Fakültesi Dergisi 48:2, pages 231-237.
Crossref
Miguel-Angel Perales, Izaskun Ceberio, Philippe Armand, Linda J. Burns, Robert Chen, Peter D. Cole, Andrew M. Evens, Ginna G. Laport, Craig H. Moskowitz, Uday Popat, Nishitha M. Reddy, Thomas C. Shea, Julie M. Vose, Jeffrey Schriber, Bipin N. Savani & Paul A. Carpenter. (2015) Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 21:6, pages 971-983.
Crossref
Daniel Spira, Leonard Grünwald, Wichard Vogel, Alexander Sauter, Sven Michael Spira, Claus Detlef Claussen & Marius Horger. (2014) Midtreatment Evaluation of Lymphoma Response to Chemotherapy by Volume Perfusion Computed Tomography. Journal of Computer Assisted Tomography 38:1, pages 123-130.
Crossref
Basem M. William, Fausto R. LoberizaJr.Jr., Victoria Whalen, Philip J. Bierman, R. Gregory Bociek, Julie M. Vose & James O. Armitage. (2013) Impact of Conditioning Regimen on Outcome of 2-Year Disease-Free Survivors of Autologous Stem Cell Transplantation for Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 417-423.
Crossref
Laura Labonté, Yuhua Li, Lin Yang, Akira Gillingham, Michael Halpenny, Antonio Giulivi, Terrence Sills, Kenneth Evans, Brent Zanke & David S. Allan. (2009) Increased plasma EPO and MIP-1α are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts. Experimental Hematology 37:6, pages 673-678.
Crossref
T Seshadri, M Pintilie, A Keating, M Crump & J Kuruvilla. (2008) The relationship between absolute lymphocyte count with PFS in patients with Hodgkin's lymphoma undergoing autologous hematopoietic cell transplant. Bone Marrow Transplantation 42:1, pages 29-34.
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:2, pages 115-122.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.